A
aTyr Pharma, Inc. (ATYR)
NCM – Real vaqt narxi. Valyuta: USD
0.53
-0.42 (-44.20%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.53
-0.42 (-44.20%)
Yopilishda: May 12, 2026, 4:00 PM EDT
aTyr Pharma, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, AQShda fibroz va yallig'lanishni davolash uchun tRNK sintaza biologiyasini yangi dorilarga aylantiradigan mahsulot nomzodlarini kashf etish va ishlab chiqish bilan shug'ullanadi. Uning asosiy terapevtik nomzodi efzofitimod, NRP2 ning selektiv modulatori, pulmoner sarkoidozni davolash uchun 3-bosqich klinik sinovda; Sarkoidoz va tizimli skleroz - o'pka kasalligi (ILD)ni davolash uchun 2-bosqich klinik sinovda; va surunkali gipersensitiv pnevmoniya (CHP) va biriktiruvchi to'qima kasalliklari bilan bog'liq ILD kabi boshqa ILDlarni davolash. Kompaniya fibrozni davolash uchun preklinik rivojlanishda bo'lgan aspartil-tRNK sintaza domenidan olingan fuzion oqsil ATYR0101 va jigar kasalliklarini davolash uchun alanil-tRNK sintaza domeni ATYR0750ni ishlab chiqmoqda. Kompaniya Yaponiyada ILDlar uchun efzofitimodni ishlab chiqish va tijoratlashtirish bo'yicha Kyorin Pharmaceutical Co., Ltd. bilan hamkorlik va litsenzion shartnomaga ega. aTyr Pharma, Inc. 2005 yilda tashkil etilgan va shtab-kvartirasi San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Leslie Nangle Ph.D. | Vice President of Research |
| Dr. Sanjay S. Shukla M.D., M.S. | President, CEO & Director |
| Mr. Peter Villiger | Vice President of Corporate Development |
| Ms. Ashlee Dunston | Director of Investor Relations & Corporate Communications |
| Ms. Dalia R. Rayes M.B.A. | Head of Commercial, Global Efzofitimod Franchise |
| Ms. Danielle Campbell | VP of Human Resource |
| Ms. Nancy E. Denyes Krueger J.D. | General Counsel & Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-26 | DEFA14A | defa14a_2026_naa_proxy_c.htm |
| 2026-03-12 | PRE 14A | atyr-20260312.htm |
| 2026-03-05 | 10-K | atyr-20251231.htm |
| 2025-12-05 | 8-K | atyr-20251204.htm |
| 2025-11-06 | 8-K | atyr-20251106.htm |
| 2025-11-06 | 10-Q | atyr-20250930.htm |
| 2025-09-15 | 8-K | atyr-20250915.htm |
| 2025-08-13 | CORRESP | filename1.htm |
| 2025-08-08 | 8-K/A | atyr-20250807.htm |
| 2025-08-07 | S-3 | atyr-20250807.htm |